Relapse after CAR-T liked to shorter survival among younger patients with ALL

February 23, 2021

2 min read

Source/Disclosures

Published by:

Source:

Stefanski HE, et al. Abstract 126. Presented at: The 2021 TCT Meetings Digital Experience (virtual meeting); Feb. 8-12, 2021.

Disclosures: Stefanski reports advisory board and speakers bureau roles with Novartis. Please see the abstract for all other researchers’ relevant financial disclosures.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

ADDED TO EMAIL ALERTS

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Younger patients who experienced disease progression after CD19-directed chimeric antigen receptor T-cell therapy had significantly shorter OS than those who did not relapse, according to results presented at TCT Meetings Digital Experience.

Results of the retrospective study also showed a lack of a standard approach to salvage therapy for patients who relapse after CAR T-cell therapy, according to Heather E…

..

Want to know more click here go to source.

From Healio - February 23, 2021